Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
BACKGROUND
Patients with cancer are considered highly vulnerable to the recent coronavirus disease 2019 (COVID-19) pandemic. However, there are still few data on COVID-19 occurring in hematologic patients.


METHODS
One hundred two patients with COVID-19 symptoms and a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 seen at 2 hematologic departments located in Lombardy, Italy, during March 2020 were studied. Risk factors for acquiring COVID-19 were analyzed by comparisons of patients with COVID-19 and the standard hematologic population managed at the same institutions in 2019. Thirty-day survival was compared with the survival of matched uninfected control patients with similar hematologic disorders and nonhematologic patients affected by COVID-19.


RESULTS
Male sex was significantly more prevalent in patients with COVID-19. The infection occurred across all different types of hematologic disease; however, the risk of acquiring a COVID-19 infection was lower for patients with chronic myeloproliferative neoplasms, including chronic myeloid leukemia, and higher for patients with immune-mediated anemia on immunosuppressive-related treatments. The 30-day mortality rate was 39.2%, which was higher than the rates for nonhematologic patients with COVID-19 (23.5%; P = .02) and uninfected hematologic controls (3%; P < .001). The severity of the respiratory syndrome at presentation and active hematologic treatment were independently associated with a worse prognosis. Neither diagnosis nor disease status affected the prognosis. The worst prognosis was demonstrated among patients on active hematologic treatment and those with more severe respiratory syndrome at COVID-19 presentation.


CONCLUSIONS
During the COVID-19 pandemic, patients should be advised to seek medical attention at the earliest signs of dyspnea and/or respiratory infection. Physicians should perform a risk-benefit analysis to determine the impact of temporarily deferring nonlifesaving treatments versus the risk of adverse outcomes associated with COVID-19.


LAY SUMMARY
Coronavirus disease 2019 (COVID-19) infection occurs across all different types of hematologic disease; however, the risk of acquiring it is lower for patients with chronic myeloproliferative neoplasms, including chronic myeloid leukemia, and higher for patients with immune-mediated anemia on immunosuppressive treatment. The 30-day mortality rate is 39.2%, which is far higher than the rates for both uninfected hematologic controls (3%; P < .001) and nonhematologic patients with COVID-19 (23.5%; P = .02) despite matching for age, sex, comorbidities, and severity of disease. Variables independently associated with a worse prognosis are the severity of the respiratory syndrome at presentation and any type of active hematologic treatment. Neither diagnosis nor disease status influence the prognosis.
['Cattaneo|Chiara|C|0000-0003-0031-3237', 'Daffini|Rosa|R|', 'Pagani|Chiara|C|', 'Salvetti|Massimo|M|', 'Mancini|Valentina|V|', 'Borlenghi|Erika|E|0000-0002-4666-3817', "D'Adda|Mariella|M|", 'Oberti|Margherita|M|', 'Paini|Anna|A|', 'De Ciuceis|Carolina|C|', 'Barbullushi|Kordelia|K|', 'Cancelli|Valeria|V|', 'Belotti|Angelo|A|0000-0002-0617-3127', 'Re|Alessandro|A|0000-0003-1156-6395', 'Motta|Marina|M|', 'Peli|Annalisa|A|', 'Bianchetti|Nicola|N|', 'Anastasia|Antonella|A|', 'Dalceggio|Daniela|D|', 'Roccaro|Aldo M|AM|', 'Tucci|Alessandra|A|', 'Cairoli|Roberto|R|', 'Muiesan|Maria Lorenza|ML|', 'Rossi|Giuseppe|G|']
D000368:Aged D000073640:Betacoronavirus D000086382:COVID-19 D018352:Coronavirus Infections D005260:Female D005500:Follow-Up Studies D019337:Hematologic Neoplasms D006801:Humans D007558:Italy D008297:Male D058873:Pandemics D011024:Pneumonia, Viral D011379:Prognosis D012189:Retrospective Studies D012307:Risk Factors D000086402:SARS-CoV-2 D015996:Survival Rate
risk factors hematologic patients coronavirus disease 2019 (COVID-19) outcome epidemiology